GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vericel Corp (NAS:VCEL) » Definitions » Cyclically Adjusted Revenue per Share

Vericel (Vericel) Cyclically Adjusted Revenue per Share : $3.32 (As of Mar. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Vericel Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Vericel's adjusted revenue per share for the three months ended in Mar. 2024 was $1.065. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $3.32 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Vericel's average Cyclically Adjusted Revenue Growth Rate was 13.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 17.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 16.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 15.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Vericel was 18.10% per year. The lowest was -25.50% per year. And the median was 15.10% per year.

As of today (2024-05-28), Vericel's current stock price is $47.73. Vericel's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $3.32. Vericel's Cyclically Adjusted PS Ratio of today is 14.38.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vericel was 31.79. The lowest was 1.93. And the median was 8.96.


Vericel Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Vericel's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vericel Cyclically Adjusted Revenue per Share Chart

Vericel Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.83 2.00 2.40 2.79 3.23

Vericel Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.93 3.06 3.10 3.23 3.32

Competitive Comparison of Vericel's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Vericel's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vericel's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vericel's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vericel's Cyclically Adjusted PS Ratio falls into.



Vericel Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vericel's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.065/131.7762*131.7762
=1.065

Current CPI (Mar. 2024) = 131.7762.

Vericel Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.680 100.560 0.891
201409 0.940 100.428 1.233
201412 0.618 99.070 0.822
201503 0.456 99.621 0.603
201506 0.571 100.684 0.747
201509 0.475 100.392 0.623
201512 0.651 99.792 0.860
201603 0.624 100.470 0.818
201606 0.565 101.688 0.732
201609 0.481 101.861 0.622
201612 0.679 101.863 0.878
201703 0.293 102.862 0.375
201706 0.517 103.349 0.659
201709 0.424 104.136 0.537
201712 0.666 104.011 0.844
201803 0.499 105.290 0.625
201806 0.496 106.317 0.615
201809 0.524 106.507 0.648
201812 0.721 105.998 0.896
201903 0.499 107.251 0.613
201906 0.595 108.070 0.726
201909 0.654 108.329 0.796
201912 0.880 108.420 1.070
202003 0.594 108.902 0.719
202006 0.443 108.767 0.537
202009 0.682 109.815 0.818
202012 0.841 109.897 1.008
202103 0.752 111.754 0.887
202106 0.852 114.631 0.979
202109 0.739 115.734 0.841
202112 1.016 117.630 1.138
202203 0.768 121.301 0.834
202206 0.786 125.017 0.828
202209 0.817 125.227 0.860
202212 1.116 125.222 1.174
202303 0.866 127.348 0.896
202306 0.965 128.729 0.988
202309 0.957 129.860 0.971
202312 1.361 129.419 1.386
202403 1.065 131.776 1.065

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Vericel  (NAS:VCEL) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Vericel's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=47.73/3.32
=14.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vericel was 31.79. The lowest was 1.93. And the median was 8.96.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Vericel Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Vericel's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Vericel (Vericel) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vericel Corp (NAS:VCEL) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
64 Sidney Street, Cambridge, MA, USA, 02139
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in advanced therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
Executives
Dominick Colangelo director, officer: President and CEO 1000 WINTER ST., SUITE 2200, WALTHAM MA 02451
Zerbe Robert L Md director
Paul K Wotton director C/O ANTARES PHARMA, INC., 707 EAGLEVIEW BOULEVARD, SUITE 414, EXTON PA 19341
Sean C. Flynn officer: SVP, General Counsel C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Michael Halpin officer: Chief Operating Officer C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Jonathan Mark Hopper officer: Chief Medical Officer 64 SIDNEY STREET, CAMBRIDGE MA 02139
Jonathan Siegal officer: Principal Accounting Officer C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Lisa Wright director C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Mara Joseph Anthony Jr officer: Chief Financial Officer C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Sandra Pennell officer: VP and Corporate Controller C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Gerard J Michel officer: CFO & VP , Corp. Development 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Daniel Orlando officer: Chief Operating Officer P.O. BOX 376, ANN ARBOR MI 48105
Alan L Rubino director PO BOX 376, LOBBY L., ANN ARBOR MI 48105
Consonance Capital Management Lp 10 percent owner 1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK NY 10019